{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:24:24Z","timestamp":1784582664063,"version":"3.55.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hoc.2025.05.004","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T19:23:06Z","timestamp":1752693786000},"page":"845-858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Autonomous B-cell Receptor Signaling in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"39","author":[{"given":"Anastasia","family":"Iatrou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Agathangelidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Bordini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Stamatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.hoc.2025.05.004_bib1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.004_bib2","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2010-07-155663","article-title":"Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities","volume":"117","author":"Chiorazzi","year":"2011","journal-title":"Blood"},{"issue":"04","key":"10.1016\/j.hoc.2025.05.004_bib3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.17925\/EOH.2010.04.0.80","article-title":"Recurrent genomic aberrations in chronic lymphocytic leukaemia \u2013 implications for disease pathogenesis and prognosis","volume":"00","author":"Mansouri","year":"2010","journal-title":"Eur Oncol Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.004_bib4","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41375-022-01802-y","article-title":"Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY","volume":"37","author":"Mansouri","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.004_bib5","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/bjc.2016.78","article-title":"The clinical implications of gene mutations in chronic lymphocytic leukaemia","volume":"114","author":"Rossi","year":"2016","journal-title":"Br J Cancer"},{"issue":"26","key":"10.1016\/j.hoc.2025.05.004_bib6","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.hoc.2025.05.004_bib7","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","article-title":"B-cell receptor signaling in chronic lymphocytic leukemia","volume":"118","author":"Stevenson","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.004_bib8","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.004_bib9","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.004_bib10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.004_bib11","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/sj.leu.2403312","article-title":"Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated?","volume":"18","author":"Forconi","year":"2004","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.004_bib12","first-page":"1","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.004_bib13","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1172\/JCI3009","article-title":"Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors","volume":"102","author":"Fais","year":"1998","journal-title":"J Clin Investig"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.004_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2006-03-012948","article-title":"Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations","volume":"109","author":"Stamatopoulos","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.004_bib15","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2007-07-099564","article-title":"Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis","volume":"111","author":"Murray","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.004_bib16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/leu.2016.322","article-title":"Antigen receptor stereotypy in chronic lymphocytic leukemia","volume":"31","author":"Stamatopoulos","year":"2017","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.hoc.2025.05.004_bib17","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1182\/blood-2011-11-393694","article-title":"Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies","volume":"119","author":"Agathangelidis","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.004_bib18","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2020007039","article-title":"Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL","volume":"137","author":"Agathangelidis","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.004_bib19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3324\/haematol.2016.141812","article-title":"Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors","volume":"101","author":"Sutton","year":"2016","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.hoc.2025.05.004_bib20","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/onc.2012.411","article-title":"The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia","volume":"32","author":"Malek","year":"2013","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.004_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3324\/haematol.2009.021014","article-title":"High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with \u2018stereotyped\u2019 IGHV3-21 and IGHV4-34 B-cell receptors","volume":"95","author":"Marincevic","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.004_bib22","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/S2352-3026(14)00005-2","article-title":"Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study","volume":"1","author":"Baliakas","year":"2014","journal-title":"Lancet Haematol"},{"issue":"APR","key":"10.1016\/j.hoc.2025.05.004_bib23","article-title":"Chronic lymphocytic leukemia B-cell normal cellular counterpart: clues from a functional perspective","volume":"9","author":"Darwiche","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.004_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.beha.2010.02.001","article-title":"Chronic lymphocytic leukemia: a disease of activated monoclonal B cells","volume":"23","author":"Damle","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.004_bib25","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1182\/blood.V99.11.4087","article-title":"B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes","volume":"99","author":"Damle","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.004_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0896-8411(88)90068-6","article-title":"Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies","volume":"1","author":"Br\u00f6ker","year":"1988","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.004_bib27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1084\/jem.169.1.255","article-title":"Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia","volume":"169","author":"Sthoeger","year":"1989","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.004_bib28","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood-2007-11-125450","article-title":"A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies","volume":"111","author":"Myhrinder","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.004_bib29","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1172\/JCI24387","article-title":"Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity","volume":"115","author":"Herv\u00e9","year":"2005","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.004_bib30","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.2300330","article-title":"N-glycosylation of the Ig receptors shapes the antigen reactivity in chronic lymphocytic leukemia subset #201","volume":"211","author":"Iatrou","year":"2023","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.004_bib31","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10495-006-0581-z","article-title":"Identification of poly-reactive natural IgM antibody that recognizes late apoptotic cells and promotes phagocytosis of the cells","volume":"12","author":"Fu","year":"2007","journal-title":"Apoptosis"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.004_bib32","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1084\/jem.179.4.1317","article-title":"Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes","volume":"179","author":"Casciola-Rosen","year":"1994","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.004_bib33","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nri1456","article-title":"A protective role for innate immunity in systemic lupus erythematosus","volume":"4","author":"Carroll","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"3\u20134","key":"10.1016\/j.hoc.2025.05.004_bib34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/10428199409056283","article-title":"Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment","volume":"13","author":"Molica","year":"1994","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.004_bib35","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/leu.2008.379","article-title":"Molecular evidence for EBV and CMV persistence in a subset of patients with chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors","volume":"23","author":"Kostareli","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.004_bib36","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","article-title":"Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin\u2019s lymphoma: a multicenter Italian experience","volume":"23","author":"Vallisa","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.004_bib37","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood-2006-08-044008","article-title":"Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia","volume":"109","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.004_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2362.2009.02131.x","article-title":"Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia","volume":"39","author":"Steininger","year":"2009","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.004_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.20121801","article-title":"A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi","volume":"210","author":"Hoogeboom","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.hoc.2025.05.004_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.771454","article-title":"Distinctive signaling profiles with distinct biological and clinical implications in aggressive CLL subsets with stereotyped B-Cell receptor immunoglobulin","volume":"11","author":"Gerousi","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.hoc.2025.05.004_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.592205","article-title":"Proliferative signals in chronic lymphocytic leukemia; what are we missing?","volume":"10","author":"Haselager","year":"2020","journal-title":"Front Oncol"},{"issue":"6\u20137","key":"10.1016\/j.hoc.2025.05.004_bib42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.molimm.2004.04.008","article-title":"B cell antigen receptor signaling 101","volume":"41","author":"Dal Porto","year":"2004","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.004_bib43","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2008.346","article-title":"Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells","volume":"23","author":"Gobessi","year":"2009","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.004_bib44","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/leu.2012.24","article-title":"Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B cell activation and migration","volume":"26","author":"Hoellenriegel","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.004_bib45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.hoc.2025.05.004_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687458","article-title":"Targeting Bruton\u2019s tyrosine kinase in CLL","volume":"12","author":"Ahn","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.004_bib47","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.immuni.2010.06.006","article-title":"Intrinsic properties of immunoglobulin IgG1 isotype-switched B cell receptors promote microclustering and the initiation of signaling","volume":"32","author":"Liu","year":"2010","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.004_bib48","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/cancers14061489","article-title":"Targeting the non-canonical NF-\u03baB pathway in chronic lymphocytic leukemia and multiple myeloma","volume":"14","author":"Burley","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hoc.2025.05.004_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1339620","article-title":"B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia","volume":"14","author":"Schmid","year":"2024","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.004_bib50","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.004_bib51","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.4049\/jimmunol.1502297","article-title":"B cell anergy modulated by TLR1\/2 and the miR-17\u223c92 cluster underlies the indolent clinical course of chronic lymphocytic leukemia stereotyped subset #4","volume":"196","author":"Ntoufa","year":"2016","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.004_bib52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.004_bib53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.004_bib54","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"De Rooij","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2025.05.004_bib55","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.004_bib56","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.004_bib57","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2025.05.004_bib58","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2019-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.004_bib59","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.004_bib60","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"13","key":"10.1016\/j.hoc.2025.05.004_bib61","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"7415","key":"10.1016\/j.hoc.2025.05.004_bib62","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signaling","volume":"489","author":"D\u00fchren-von Minden","year":"2012","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.004_bib63","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2014-07-587790","article-title":"Two types of BCR interactions are positively selected during leukemia development in the E\u03bc-TCL1 transgenic mouse model of CLL","volume":"125","author":"Iacovelli","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.004_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15746","article-title":"Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia","volume":"8","author":"Minici","year":"2017","journal-title":"Nat Commun"},{"issue":"14","key":"10.1016\/j.hoc.2025.05.004_bib65","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1182\/blood.2020005216","article-title":"Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169","volume":"137","author":"Gemenetzi","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.004_bib66","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1182\/blood-2023-181702","article-title":"Evidence of defective cell-autonomous signalling by B cell receptors in CLL stereotyped subset #1","volume":"142","author":"Minici","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2025.05.004_bib67","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1182\/blood-2014-09-603217","article-title":"Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8","volume":"125","author":"Gounari","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.004_bib68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ajh.23591","article-title":"Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients\u2019 prognosis","volume":"89","author":"Del Giudice","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.004_bib69","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","article-title":"Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification","volume":"126","author":"Strati","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.004_bib70","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cyto.b.20174","article-title":"Prevalence and natural history of monoclonal and polyclonal B-cell lymphocytosis in a residential adult population","volume":"72","author":"Shim","year":"2007","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.004_bib71","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood-2003-09-3277","article-title":"Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly","volume":"103","author":"Ghia","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.004_bib73","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3324\/haematol.2022.282542","article-title":"Autonomous B-cell receptor signaling and genetic aberrations in chronic lymphocytic leukemia-phenotype monoclonal B lymphocytosis in siblings of patients with chronic lymphocytic leukemia","volume":"109","author":"Quinten","year":"2024","journal-title":"Haematologica"},{"issue":"7\u201312","key":"10.1016\/j.hoc.2025.05.004_bib74","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2119\/2005-00001.Stamatopoulos","article-title":"Immunoglobulin heavy- and light-chain repertoire in splenic marginal zone lymphoma","volume":"10","author":"Stamatopoulos","year":"2004","journal-title":"Mol Med"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.004_bib75","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/1078-0432.CCR-15-1170","article-title":"An immunogenetic signature of ongoing antigen interactions in splenic marginal zone lymphoma expressing IGHV1-2\u221704 receptors","volume":"22","author":"Bikos","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.004_bib76","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2012.3","article-title":"Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications","volume":"26","author":"Bikos","year":"2012","journal-title":"Leukemia"},{"issue":"S3","key":"10.1016\/j.hoc.2025.05.004_bib77","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000971780.84836.69","article-title":"P1222: antigen-independent, cell-autonomous signaling in splenic marginal zone lymphoma","volume":"7","author":"Iatrou","year":"2023","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.004_bib78","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2024-206746","article-title":"Structural and functional analysis of the clonotypic B cell receptor immunoglobulin in splenic marginal zone lymphoma: ontogenetic and therapeutic implications","volume":"144","author":"Iatrou","year":"2024","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:50:57Z","timestamp":1760503857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0889858825000760"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autonomous B-cell Receptor Signaling in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}